Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocept Inc (NQ: BIOC )

1.170 -0.030 (-2.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 59,008
Open 1.160
Bid (Size) 1.140 (1)
Ask (Size) 1.200 (4)
Prev. Close 1.200
Today's Range 1.160 - 1.198
52wk Range 0.8400 - 4.440
Shares Outstanding 16,922,868
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 77 companies made new 52-week lows. 
Via Benzinga
Biocept Appoints RSM as Independent Auditor
From Biocept, Inc.
Via Business Wire

Performance

YTD
-70.53%
-70.53%
1 Month
+19.38%
+19.38%
3 Month
-24.03%
-24.03%
6 Month
-52.24%
-52.24%
1 Year
-71.94%
-71.94%

More News

Read More
Recap: Biocept Q4 Earnings
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Biocept to Hold Business Strategy Conference Call Today
From Biocept, Inc.
Via Business Wire
Biocept's Return On Capital Employed Overview
Via Benzinga
Biocept Reports First Quarter 2022 Financial Results
From Biocept, Inc.
Via Business Wire
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Via Benzinga
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
From Biocept, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Biocept, Inc.
Via Business Wire
Looking Into Biocept's Return On Capital Employed
Via Benzinga
Biocept Reports 2021 Fourth Quarter and Full Year Financial Results
From Biocept, Inc.
Via Business Wire
Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance
From Biocept, Inc.
Via Business Wire
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Via Benzinga
Earnings Scheduled For March 31, 2022
Via Benzinga
Earnings Outlook For Biocept
Via Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Via Benzinga
Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022
From Biocept, Inc.
Via Business Wire
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer
From Biocept, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.